All Stories

  1. Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2020, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  2. Complex DDIs on CYP3A and Pgp

    Article • Drug Metabolism and Disposition, May 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  3. Relationship of AUCR = CmaxR x t1/2R can provide an additional framework for DDI evaluation.

    Article • The Journal of Clinical Pharmacology, May 2018, Wiley

    Shinji Yamazaki

  4. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

    Article • Clinical Pharmacology & Therapeutics, February 2018, Wiley

    Mohamad Shebley, Shinji Yamazaki

  5. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions

    Article • Drug Metabolism and Disposition, February 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  6. Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer

    Article • Clinical Drug Investigation, December 2016, Springer Science + Business Media

    Shinji Yamazaki

  7. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2016, Informa Healthcare

    Shinji Yamazaki

  8. Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors

    Article • January 2016, Springer Science + Business Media

    Shinji Yamazaki

  9. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model

    Article • Drug Metabolism and Disposition, July 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  10. Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase

    Article • Drug Metabolism and Disposition, October 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  11. Translation of Anticancer Efficacy From Nonclinical Models to the Clinic

    Article • CPT Pharmacometrics & Systems Pharmacology, August 2014, Wiley

    Shinji Yamazaki

  12. Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1

    Article • Journal of Pharmacology and Experimental Therapeutics, July 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  13. Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors

    Article • Drug Metabolism and Disposition, April 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  14. Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib

    Article • The AAPS Journal, December 2012, American Association of Pharmaceutical Scientists (AAPS)

    Shinji Yamazaki

  15. Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes

    Article • Drug Metabolism and Disposition, November 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  16. Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models

    Article • Journal of Pharmacology and Experimental Therapeutics, November 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  17. Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available Heat Shock Protein 90 Inhibitor in a Human Tumor Xenograft Mouse Model

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  18. Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model

    Article • Drug Metabolism and Disposition, November 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  19. Application of Stable Isotope Methodology in the Evaluation of the Pharmacokinetics of (S,S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine Hydrochloride in Rats

    Article • Drug Metabolism and Disposition, February 2009, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  20. Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

    Article • Drug Metabolism and Disposition, April 2008, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  21. An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

    Article • Cancer Research, April 2007, American Association for Cancer Research (AACR)

    Shinji Yamazaki

  22. COMPARISON OF PREDICTION METHODS FOR IN VIVO CLEARANCE OF (S,S)-3-[3-(METHYLSULFONYL)PHENYL]-1-PROPYLPIPERIDINE HYDROCHLORIDE, A DOPAMINE D2 RECEPTOR ANTAGONIST, IN HUMANS

    Article • Drug Metabolism and Disposition, March 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Shinji Yamazaki

  23. Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase

    Article • Xenobiotica, January 2001, Taylor & Francis

    Shinji Yamazaki

  24. Cholesterol 7-hydroperoxides in rat skin as a marker for lipid peroxidation

    Article • Biochemical Pharmacology, November 1999, Elsevier

    Shinji Yamazaki

  25. Quantitative determination of cholesterol 5α-, 7α-, and 7β-hydroperoxides in rat skin

    Article • Free Radical Biology and Medicine, July 1999, Elsevier

    Shinji Yamazaki

  26. Increases in cholesterol 7-hydroperoxides in lipids of human skin by sunlight exposure

    Article • Free Radical Biology and Medicine, May 1999, Elsevier

    Shinji Yamazaki

  27. Accumulation of the Toxic Steroids, Cholesterol 7-Hydroperoxides, in Rat Skin and Their Glutathione-dependent Reduction (Proceedings of the 23rd Symposium on Toxicology and Environmental Health)

    Article • Eisei kagaku, January 1998, Pharmaceutical Society of Japan

    Shinji Yamazaki

  28. Subunit Ya-specific Glutathione Peroxidase Activity toward Cholesterol 7-Hydroperoxides of GlutathioneS-Transferases in Cytosols from Rat Liver and Skin

    Article • Journal of Biological Chemistry, February 1997, American Society for Biochemistry & Molecular Biology (ASBMB)

    Shinji Yamazaki

  29. Occurrence of cholesterol 7α- and 7β-hydroperoxides in rat skin as aging markers

    Article • Biochemical and Biophysical Research Communications, July 1991, Elsevier

    Shinji Yamazaki